IL115376A - Pharmaceutical compositions comprising estramustine - Google Patents

Pharmaceutical compositions comprising estramustine

Info

Publication number
IL115376A
IL115376A IL11537695A IL11537695A IL115376A IL 115376 A IL115376 A IL 115376A IL 11537695 A IL11537695 A IL 11537695A IL 11537695 A IL11537695 A IL 11537695A IL 115376 A IL115376 A IL 115376A
Authority
IL
Israel
Prior art keywords
estramustine
pct
date
sec
image
Prior art date
Application number
IL11537695A
Other languages
English (en)
Other versions
IL115376A0 (en
Inventor
Alessandro Martini
Giuseppe Maccari
Lorena Muggetti
Giuseppe Colombo
Giovanni Buzzi
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of IL115376A0 publication Critical patent/IL115376A0/xx
Publication of IL115376A publication Critical patent/IL115376A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL11537695A 1994-09-22 1995-09-21 Pharmaceutical compositions comprising estramustine IL115376A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9419153A GB9419153D0 (en) 1994-09-22 1994-09-22 Estramustine formulations with improved pharmaceutical properties

Publications (2)

Publication Number Publication Date
IL115376A0 IL115376A0 (en) 1995-12-31
IL115376A true IL115376A (en) 1999-05-09

Family

ID=10761769

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11537695A IL115376A (en) 1994-09-22 1995-09-21 Pharmaceutical compositions comprising estramustine

Country Status (27)

Country Link
US (1) US5712260A (fr)
EP (1) EP0730474B1 (fr)
JP (1) JP3568957B2 (fr)
KR (1) KR960705587A (fr)
CN (1) CN1135719A (fr)
AT (1) ATE219378T1 (fr)
AU (1) AU698425B2 (fr)
CA (1) CA2174968A1 (fr)
CZ (1) CZ292125B6 (fr)
DE (1) DE69527129T2 (fr)
DK (1) DK0730474T3 (fr)
ES (1) ES2179115T3 (fr)
FI (1) FI962120A (fr)
GB (1) GB9419153D0 (fr)
HU (1) HUT75935A (fr)
IL (1) IL115376A (fr)
MX (1) MX9601852A (fr)
MY (1) MY115689A (fr)
NO (1) NO314438B1 (fr)
NZ (1) NZ292895A (fr)
PL (1) PL183132B1 (fr)
PT (1) PT730474E (fr)
RU (1) RU2179036C2 (fr)
TW (1) TW496739B (fr)
UA (1) UA48126C2 (fr)
WO (1) WO1996009072A1 (fr)
ZA (1) ZA957938B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GB9921958D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
ITMI20031015A1 (it) * 2003-05-20 2004-11-21 Naxospharma S R L Poli-(amminopirrolcarbossammidi) per uso nella profilassi e nel trattamento delle endoparassitosi animali e loro composizioni con ciclodestrine.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299104A (en) * 1963-04-09 1967-01-17 Leo Ab Certain steroid nu-bis-(haloethyl)-carbamates
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物
SE8802402D0 (sv) * 1988-06-28 1988-06-28 Pharmacia Ab Novel esters
GB8920135D0 (en) * 1989-09-06 1989-10-18 Erba Carlo Spa Use of dehydrated cyclodextrins for improving drug dissolution
FR2667070A1 (fr) * 1990-09-21 1992-03-27 Besins Iscovesco Labo Sterouides inclus dans des cyclodextrines procede pour leur preparation complexes et formes goleniques correspondants et leurs applications therapeutiques.

Also Published As

Publication number Publication date
JPH09505832A (ja) 1997-06-10
EP0730474A1 (fr) 1996-09-11
FI962120A0 (fi) 1996-05-20
AU3519995A (en) 1996-04-09
NZ292895A (en) 1998-04-27
PT730474E (pt) 2002-11-29
PL183132B1 (pl) 2002-05-31
AU698425B2 (en) 1998-10-29
NO961979D0 (no) 1996-05-14
KR960705587A (ko) 1996-11-08
MY115689A (en) 2003-08-30
RU2179036C2 (ru) 2002-02-10
DE69527129T2 (de) 2003-03-06
NO314438B1 (no) 2003-03-24
DE69527129D1 (de) 2002-07-25
JP3568957B2 (ja) 2004-09-22
WO1996009072A1 (fr) 1996-03-28
DK0730474T3 (da) 2002-09-23
CZ292125B6 (cs) 2003-08-13
GB9419153D0 (en) 1994-11-09
MX9601852A (es) 1997-03-29
ES2179115T3 (es) 2003-01-16
CZ145696A3 (en) 1996-08-14
CA2174968A1 (fr) 1996-03-28
HU9601738D0 (en) 1996-08-28
ATE219378T1 (de) 2002-07-15
NO961979L (no) 1996-05-14
PL314584A1 (en) 1996-09-16
UA48126C2 (uk) 2002-08-15
FI962120A (fi) 1996-05-20
TW496739B (en) 2002-08-01
ZA957938B (en) 1996-04-18
IL115376A0 (en) 1995-12-31
HUT75935A (en) 1997-05-28
CN1135719A (zh) 1996-11-13
EP0730474B1 (fr) 2002-06-19
US5712260A (en) 1998-01-27

Similar Documents

Publication Publication Date Title
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
LU91206I2 (fr) Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel)
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
CA2302568A1 (fr) Procede, compositions et trousses servant a augmenter la biodisponibilite orale d'agents pharmaceutiques
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
IL115184A0 (en) Anthracycline derivatives their preparation and use
IL115376A (en) Pharmaceutical compositions comprising estramustine
PL322872A1 (en) Novel triazolones - inhibitors of b apolipoprotein synthesis
HU9600758D0 (en) Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
ZA956476B (en) N-substituted azobiccloheptane derivatives, the preparation and use thereof.
NZ292934A (en) Amino substituted indole ether derivatives and medicaments
CA2284041A1 (fr) Indolecarboxamides, compositions pharmaceutiques et procedes d'inhibition de la calpaine
ZA935045B (en) Pharmacologically active alfa-(tertiary-aminomethyl)-ben-zenemethanol derivatives
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств
AU4544096A (en) New derivatives of glycylanilides, preparation and therapeutical application
IT1252169B (it) Composizioni terapeutiche adatte per la somministrazione orale contenenti come principio attivo uno o piu' tioesteri del glutatione, e procedimento per la preparazione dei suddetti principi attivi
RU97113700A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики ожирения
RU98114985A (ru) Применение 3,4-дифенилхроманов для производства фармацевтического состава для лечения или профилактики симптомов менопаузы

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees